Treats benign prostatic hyperplasia (BPH). ANDA 78801, held by Synthon. Tamsulosin Hydrochloride.
As of Nov 21, 2026, ANDA 78801 (Tamsulosin Hydrochloride), held by Synthon, was first approved by FDA on Apr 27, 2010, with 3 approved supplements and 0 published complete response letters.
Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. Tamsulosin hydrochloride capsules are an alpha 1 adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 27, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tamsulosin Hydrochloride0.4MG · capsule;oral | Tamsulosin Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 16Manufacturing | Approved | None posted |
| Nov 2, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 17, 2011 | Supplement 4Labeling | Approved | None posted |
| Apr 27, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters